$NOVO B #Novo Nordisk A/S B Novo Nordisk - Another phase 3 slam dunk with sema obesity: Second phase 3 data with semaglutide obesity 14.9% weight loss with sema (16.9% if taken as intended) Another strong step in the right strategic… https://t.co/XN7v5RAeyD #equity #stocks https://t.co/Y9GcrlcjCg